Articles
Natural killers: a new tactical unit joins the cancer immunotherapy brigade
There was a time when all that oncologists treating solid tumours needed to know about leukocytes was how to measure the damage that cytotoxic drugs inflicted on their patients’ white…
Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
Adverse effects of cancer therapies have long been at the root of decision making for interventions in all modalities – surgery, radiotherapy and medical – and especially in the latter…
Beating cancer is complex – our messaging must be clear
With the launch of Europe’s Beating Cancer Plan, the Cancer Mission, and the EU4Health programme, the European Commission has offered an ambitious vision, a road map and momentum. Anna Wagstaff…
Who wouldn’t want to cure 100% of childhood cancers?
More than eight in ten children and young adults diagnosed with cancer now survive their disease, often going on to live long and fulfilling lives. But the serious life-long damage…
Berlin pilot project brings precision care to the peripheries
An innovative network in Germany is giving men with advanced prostate cancer access to cutting-edge precision medicine – even if they live in remote areas. Patient organisations are wondering whether…
Highlights of 2020 American Society of Hematology (ASH) meeting
Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent…
Highlights of 2020 San Antonio Breast Cancer Symposium
In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast…
The sunshine hormone: the many wonders of vitamin D
Vitamin D has drawn much scientific interest and media coverage in recent years, and increasingly so in 2020, when a link was found between vitamin D deficiency and Covid-19. This…
EMA at 25: learning more from cancer patients
The European Medicines Agency is 25 years old this year. To mark the occasion, the agency invited leading voices from parts of the cancer community to share their perspectives on…
Oncolytic viruses – a new wave of therapeutic possibilities
Over the past two decades, significant advances have been made with oncolytic viral therapies. The lack of long-lasting adverse effects, and synergy with immunotherapy combinations, make them an attractive therapeutic…